South Korea Migraine Drugs Market

ID: MRFR/MED/49252-HCR

200 Pages

Rahul Gotadki

September 2025

South Korea Migraine Drugs Market Research Report By End-User (Hospitals And Clinics, Retail Pharmacy, Online Pharmacy, Others), By Type (Episodic Migraine, Chronic Migraine), By Treatment Type (Acute, Preventive, Neuromodulation Devices) and By Drug Class (Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants) - Forecast to 2035

South Korea Migraine Drugs Market Infographic

Single User

$ 4,950.0

Multiple License

$ 5,950.0

Enterprise User

$ 7,250.0

Summary Table of Contents Segmentation Infographic

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

South Korea Migraine Drugs Market Summary

The South Korea migraine drugs market is poised for growth, projected to reach 215.9 million USD by 2035.

Key Market Trends & Highlights

South Korea Migraine Drugs Key Trends and Highlights

The market valuation for migraine drugs in South Korea is 136.8 million USD in 2024.
By 2035, the market is expected to expand to 215.9 million USD, indicating a robust growth trajectory.
The compound annual growth rate (CAGR) for the period from 2025 to 2035 is estimated at 4.24 percent.
Growing adoption of innovative treatment options due to increasing prevalence of migraines is a major market driver.

South Korea Migraine Drugs Market

CAGR

4.24%

Market Size & Forecast

2024 Market Size	136.8 (USD Million)
2035 Market Size	215.9 (USD Million)
CAGR (2025-2035)	4.24%

Major Players

Teva Pharmaceutical, Pfizer, Boehringer Ingelheim, Mylan, Merck, GlaxoSmithKline, Roche, AstraZeneca, Sumitomo Dainippon Pharma, Eli Lilly, Johnson & Johnson, AbbVie, Amgen, Novartis, Sanofi

South Korea Migraine Drugs Market Trends

The South Korea Migraine Drugs Market is experiencing a notable shift driven by several key market drivers. Increasing awareness about migraine as a serious health issue is prompting both healthcare providers and patients to seek effective treatments. South Korea's advanced healthcare system enables better access to various migraine medications, including preventive treatments and acute relief options. The rise in the number of migraine patients, especially among working-age adults, further drives the market as more individuals recognize the significance of timely and effective treatment for improving their quality of life.

Opportunities to be explored include the growing demand for personalized medicine.With advancements in biotechnology, pharmaceutical companies are focusing on developing targeted therapies that cater to the specific needs of patients with different migraine profiles. Additionally, the potential for expanding telemedicine services in South Korea can enhance patient engagement and facilitate timely prescriptions and consultations for those suffering from migraines.

Trends in recent times reflect an increasing emphasis on research and development efforts by South Korean pharmaceutical companies to create new migraine drugs. There is a growing interest in non-pharmacological treatments as well, such as cognitive behavioral therapy and biofeedback, indicating a more holistic approach to managing migraine.Moreover, the impact of lifestyle changes and stress management initiatives is gaining attention, in recognition of their role in migraine triggers. As South Korea continues to innovate and adapt in healthcare, the migraine drugs segment is poised for growth, driven by a combination of technological advancements and evolving patient needs.

Market Segment Insights

South Korea Migraine Drugs Market Segment Insights

Migraine Drugs Market End-User Insights

The South Korea Migraine Drugs Market exhibits a diverse range of End-User platforms pivotal for the distribution and accessibility of migraine medications. The sector encompasses Hospitals and Clinics, Retail Pharmacies, Online Pharmacies, and Other channels, each contributing significantly to the overall dynamics of the industry. Hospitals and Clinics serve as primary healthcare touchpoints, where a considerable volume of migraine treatments are prescribed and administered.

The professional healthcare setting facilitates patient evaluations and broader treatments, often leading to increased patient engagement and satisfaction with care. Moreover, hospitals and clinics are instrumental in the initial diagnosis and ongoing management of migraine patients, leveraging the expertise of specialized neurologists.Retail Pharmacies remain a critical part of the South Korea Migraine Drugs Market as they provide convenience and accessibility to a wider segment of the population.

This sector benefits from the growing consumer trend towards swift access to medications, allowing patients to obtain their prescribed migraine drugs directly in their neighborhood. The personal interaction with pharmacists further enhances patient trust and adherence to treatment regimens. Additionally, the rise in collaborations between retail pharmacies and healthcare providers has led to greater awareness and education about migraine treatments among the general public.In the digital era, Online Pharmacies have carved out an essential niche within the market, showcasing a transformative shift in how patients procure medications.

The convenience of online ordering, combined with home delivery options, addresses the preferences of a technology-savvy demographic. The omnipresence of digital platforms supports the overall growth of the South Korea Migraine Drugs Market by catering to the demands of patients seeking discretion and ease of access. This segment has significantly impacted patients' decision-making processes, with many opting for online solutions due to the increasing comfort and trust in e-commerce.Furthermore, Other channels encompass various distribution methods, including telehealth services and community health initiatives designed to raise awareness about migraine management and treatment options.

Migraine Drugs Market Type Insights

The South Korea Migraine Drugs Market is categorized by Type, including dominant categories such as Episodic Migraine and Chronic Migraine. The South Korea experiences a significant prevalence of migraines, with the episodic form being common among individuals with occasional headaches, typically occurring less than fifteen days a month.

Conversely, the chronic migraine segment represents a critical area of concern, affecting those who endure migraines on more than fifteen days per month, leading to substantial impacts on their quality of life and productivity.Given the increasing awareness about migraine management and the introduction of advanced therapeutics, there is considerable growth potential in these areas.

Further, the South Korean population’s focus on healthcare advancements, coupled with rising healthcare expenditures, supports the ongoing development and enhancement of migraine drug therapies, especially for chronic migraine, which requires more intensive treatment protocols.

The significance of these segments is accentuated by the rising demand for effective treatment options, driven by lifestyle changes, stress, and environmental factors, ultimately driving growth in the South Korea Migraine Drugs Market.The challenge remains in addressing the therapy gaps, particularly for chronic migraine patients, as research and development focused on novel treatment modalities is essential in improving patient outcomes in South Korea.

Migraine Drugs Market Treatment Type Insights

The South Korea Migraine Drugs Market is significantly segmented into various treatment types, notably Acute, Preventive, and Neuromodulation Devices. Acute treatments primarily focus on providing immediate relief during a migraine attack, catering to the needs of patients experiencing sudden, debilitating pain. Preventive treatments, on the other hand, aim to reduce the frequency and severity of migraine episodes, playing a crucial role in long-term management for chronic sufferers. With an increasing prevalence of migraine cases in South Korea, the demand for effective preventive options is notable, reflecting an evolving landscape in patient care.

Neuromodulation Devices represent a growing trend with innovative technologies offering non-pharmacological approaches to migraine management, appealing to patients who may prefer to avoid medication. The combination of these treatment types addresses the varying needs of migraine sufferers, contributing to a comprehensive strategy for alleviating the burden of this disorder. The rise in healthcare awareness, increasing access to advanced medical technologies, and the expanding pharmaceutical portfolios are propelling the growth of these treatment options in the region, driving the momentum in the South Korea Migraine Drugs Market.

Migraine Drugs Market Drug Class Insights

The South Korea Migraine Drugs Market is segmented by drug class, encompassing various categories like Triptans, Betablockers, Angiotensin Blockers, Tricyclics, and Anticonvulsants. Triptans are notable for their ability to provide quick relief from migraine attacks, making them a preferred choice among patients. Betablockers, historically used for hypertension and heart issues, have gained traction in migraine prevention due to their efficacy in reducing attack frequency. Angiotensin Blockers, although less commonly used, show potential in addressing migraine symptoms linked to vascular activity.Tricyclics, often assisting in both pain management and mood stabilization, are recognized for their role in chronic migraine treatment.

Lastly, Anticonvulsants have emerged as vital players in migraine prophylaxis, offering dual benefits by managing seizure disorders and migraines alike. The increasing recognition of these drugs in both treating and preventing migraines, coupled with ongoing research initiatives within South Korea, is expected to drive further innovation in the sector. Furthermore, the growing incidence of migraines among the population underscores the importance and relevance of these drug classes in addressing this prevalent health issue effectively.

Get more detailed insights about South Korea Migraine Drugs Market Research Report- Forecast to 2035

Request Free Sample

Key Players and Competitive Insights

The South Korea Migraine Drugs Market has displayed significant growth in recent years, driven by increasing awareness and improved diagnosis rates of migraine among the population. The competitive landscape in this market is marked by a mix of global pharmaceutical giants and local players, all vying for a share in this lucrative sector. A multitude of offerings exists in the market, ranging from over-the-counter medications to specialized prescription drugs, catering to the diverse needs of patients suffering from migraines. The evolving regulatory environment, along with advancements in drug formulations and delivery systems, enhances the competitive dynamics.

As a result, companies are focusing on innovative solutions and strategic partnerships to solidify their positions in the marketplace.Teva Pharmaceutical has established a robust presence in the South Korean Migraine Drugs Market, offering a wide range of products that cater to the various needs of migraine sufferers.

The company’s strength lies in its extensive portfolio, including both generics and specialty drugs, which helps to make treatments more accessible and affordable. Teva's commitment to research and development further enhances its competitive edge, as it continuously strives to improve existing formulations and develop new innovative therapies specifically aimed at migraine relief.

The company's established distribution networks in South Korea enable it to reach a broad audience, providing strong support for its product lines and maintaining a loyal customer base. Teva's reputation for quality and efficacy in its migraine treatments reinforces its credibility in the market.Pfizer plays a pivotal role in the South Korea Migraine Drugs Market with its innovative offerings and strategic positioning. The company is known for its flagship products targeting migraine treatments, which are highly regarded for efficacy among healthcare professionals and patients alike.

Pfizer's strengths include a strong research-driven approach that has led to successful drug development and effective therapies designed specifically for migraine relief.

The company's presence in South Korea is bolstered by comprehensive marketing strategies and collaborations with healthcare providers, ensuring broad accessibility to its products. Furthermore, Pfizer’s engagement in potential mergers and acquisitions has strengthened its portfolio and market presence, facilitating the introduction of novel solutions for migraine sufferers. This strategic focus positions Pfizer as a key player in the South Korean market, making significant contributions to migraine therapy advancements.

Key Companies in the South Korea Migraine Drugs Market market include

Industry Developments

The South Korea Migraine Drugs Market has been experiencing notable developments in recent months. Teva Pharmaceutical and AbbVie are currently focusing on expanding their product offerings, with recent launches aimed at enhancing treatment options for chronic migraine sufferers. In October 2023, Pfizer announced strategic partnerships aimed at increasing the accessibility of its migraine treatments within local markets. Meanwhile, there has been significant growth reported among companies such as Eli Lilly and Johnson and Johnson, which are leveraging innovative treatments to capture market share.

In terms of mergers and acquisitions, no recent notable transactions have been recorded for the listed companies in the South Korea Migraine Drugs Market, as various companies continue to strengthen their existing research and product lines instead. Over the past few years, regulatory reforms in South Korea have paved the way for quicker approvals of new migraine therapies, consequently impacting market dynamics positively.

Furthermore, a growing awareness regarding migraine management among healthcare professionals and patients alike has contributed to a wider adoption of preventive therapies within the region. This evolving landscape underscores the increasing importance of migraine treatment in the South Korean healthcare market.

Market Segmentation

Migraine Drugs Market Type Outlook

Episodic Migraine
Chronic Migraine

Migraine Drugs Market End-User Outlook

Hospitals And Clinics
Retail Pharmacy
Online Pharmacy
Others

Migraine Drugs Market Drug Class Outlook

Triptans
Betablockers
Angiotensin Blockers
Tricyclics
Anticonvulsants

Migraine Drugs Market Treatment Type Outlook

Acute
Preventive
Neuromodulation Devices

Report Scope

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	131.93(USD Million)
MARKET SIZE 2024	136.75(USD Million)
MARKET SIZE 2035	215.91(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	4.239% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2023
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Teva Pharmaceutical, Pfizer, Boehringer Ingelheim, Mylan, Merck, GlaxoSmithKline, Roche, AstraZeneca, Sumitomo Dainippon Pharma, Eli Lilly, Johnson & Johnson, AbbVie, Amgen, Novartis, Sanofi
SEGMENTS COVERED	End-User, Type, Treatment Type, Drug Class
KEY MARKET OPPORTUNITIES	Growing prevalence of migraine cases, Increasing demand for preventive therapies, Innovative drug development pipelines, Expansion of telehealth services, Rising awareness of migraine treatments
KEY MARKET DYNAMICS	Rising migraine prevalence, Increasing healthcare expenditure, Growing awareness of treatments, Availability of innovative drugs, Strong pharmacy distribution networks
COUNTRIES COVERED	South Korea

FAQs

What is the expected market size of the South Korea Migraine Drugs Market in 2024?

In 2024, the South Korea Migraine Drugs Market is expected to be valued at 136.75 million USD.

What is the projected value of the South Korea Migraine Drugs Market by 2035?

By 2035, the South Korea Migraine Drugs Market is projected to reach a value of 215.91 million USD.

What is the compound annual growth rate (CAGR) for the South Korea Migraine Drugs Market from 2025 to 2035?

The expected CAGR for the South Korea Migraine Drugs Market from 2025 to 2035 is 4.239%.

Which segment holds the largest market share in the South Korea Migraine Drugs Market in 2024?

In 2024, the Hospitals and Clinics segment is valued at 54.0 million USD, holding the largest market share.

What is the market size for the Retail Pharmacy segment in 2035?

The Retail Pharmacy segment is expected to be valued at 65.0 million USD in 2035.

What are some of the major players in the South Korea Migraine Drugs Market?

Major players in the market include Teva Pharmaceutical, Pfizer, Boehringer Ingelheim, and Merck.

How much is the Online Pharmacy segment projected to be valued in 2024?

The Online Pharmacy segment is projected to be valued at 25.0 million USD in 2024.

What is the growth forecast for the 'Others' segment by 2035?

The 'Others' segment is expected to reach a value of 22.91 million USD by 2035.

What opportunities exist in the South Korea Migraine Drugs Market during the forecast period?

The market presents opportunities driven by increasing healthcare access and advancements in migraine treatment options.

What challenges might impact the South Korea Migraine Drugs Market in the coming years?

Challenges may include regulatory hurdles and competition among established pharmaceutical players.

South Korea Migraine Drugs Market Research Report- Forecast to 2035 Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Customer Stories

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Victoria Milne Founder

Case Study

Chemicals and Materials

Global Magnesium Sulfate Market – Forecast till 2027